Docoh
Loading...

IOVA Iovance Biotherapeutics

APP
Utility
Systems and Methods for Determining the Beneficial Administration of Tumor Infiltrating Lymphocytes, and Methods of Use Thereof and Beneficial Administration of Tumor Infiltrating Lymphocytes, and Methods of Use Thereof
2 Dec 21
Maria Fardis, Heinrich Roder, Joanna Roder
Filed: 14 Dec 18
APP
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
25 Nov 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 22 Jul 21
APP
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
25 Nov 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 22 Jul 21
GRANT
Utility
Restimulation of cryopreserved tumor infiltrating lymphocytes
23 Nov 21
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 16 Apr 21
APP
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
18 Nov 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 22 Jul 21
GRANT
Utility
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
9 Nov 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender
Filed: 13 Jan 21
GRANT
Utility
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
9 Nov 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender
Filed: 13 Jan 21
APP
Utility
Systems and Methods for Coordinating Manufacturing of Cells for Patient-specific Immunotherapy
28 Oct 21
A method for coordinating the manufacturing of an expanded cell therapy product for a patient may include receiving a cell order request to expand the cell therapy product for the patient; generating a patient-specific identifier or cell order identifier associated with the cell order request; and initiating a process to expand the cell therapy product from at least some of a solid tumor obtained from the patient.
Anne Brooks, Steve Macrides, Kristin Lanzi
Filed: 22 Apr 21
GRANT
Utility
Programmed death 1 ligand 1 (PD-L1) binding proteins and methods of use thereof
12 Oct 21
The present disclosure provides proteins, such as antibodies, that include an antigen binding portion that specifically binds to Programmed Death 1 Ligand 1 (PD-L1).
Brian Rabinovich, Natalia Martin-Orozco, Laszlo Radvanyi
Filed: 7 Jul 17
GRANT
Utility
Restimulation of cryopreserved tumor infiltrating lymphocytes
12 Oct 21
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 16 Apr 21
APP
Utility
Til Expansion from Fine Needle Aspirates and Small Biopsies
7 Oct 21
The present disclosure provides methods for expanding TIL populations from fine needle aspirates (FNAs) or small biopsies which contain low numbers of TILs, using the methods disclosed herein including in a closed system that leads to improved phenotype and increased metabolic health of the TILs in a shorter time period.
Michelle Simpson-Abelson, Cecile Chartier-Courtaud
Filed: 18 May 21
GRANT
Utility
Restimulation of cryopreserved tumor infiltrating lymphocytes
21 Sep 21
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after restimulation.
Ian Frank, Michael T. Lotze
Filed: 16 Apr 21
APP
Utility
Expansion of TILs from Cryopreserved Tumor Samples
9 Sep 21
In some embodiments, methods of expanding tumor infiltrating lymphocytes from cryopreserved tumor tissue and methods of using the expanded tumor infiltrating lymphocytes in the treatment of human diseases, including cancers, are disclosed In some embodiments, compositions of cryopreserved tumor tissues are disclosed.
Anand Veerapathran, Kenneth Onimus
Filed: 10 Feb 21
APP
Utility
Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes
26 Aug 21
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 16 Apr 21
APP
Utility
Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes
19 Aug 21
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 16 Apr 21
APP
Utility
Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes
19 Aug 21
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 16 Apr 21
GRANT
Utility
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
10 Aug 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 2 Dec 20
APP
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
15 Jul 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender
Filed: 12 Jan 21
GRANT
Utility
Restimulation of cryopreserved tumor infiltrating lymphocytes
13 Jul 21
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 8 Apr 21
APP
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
8 Jul 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender
Filed: 13 Jan 21
Patents are sorted by USPTO publication date, most recent first